{
  "symbol": "PFE",
  "year": 2024,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.1519,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.151
  },
  "top_positive": [
    {
      "sent": "Approved April 2023 Approved March 2024 Approved March 2024 TicoVac (Vaccine) Active immunization to prevent tick-borne encephalitis in individuals 1 year of age and older Approved August 2021 Approved March 2024 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura in adults Approved February 2020 Approved April 2022 Prevention of episodic migraine in adults Approved May 2021 Approved April 2022 Penbraya (Vaccine) Active immunization to prevent serogroups ABCWY meningococcal infections in adolescents and young adults 10 through 25 years of age Approved October 2023 Filed June 2023 Abrysvo (Vaccine) Active immunization of pregnant individuals for the prevention of lower respiratory tract disease caused by RSV in infants from birth through 6 months of age Approved August 2023 Approved August 2023 Approved January 2024 Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older Approved May 2023 Approved August 2023 Approved March 2024 Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age Approved October 2024 Filed June 2024 Velsipity (etrasimod) Moderately to severely active ulcerative colitis in adults Approved October 2023 Approved February 2024 Filed June 2024 Braftovi (encorafenib) and Mektovi (binimetinib) (b) BRAF V600E -mutant metastatic non-small cell lung cancer in adult patients Approved October 2023 Approved August 2024 Elrexfio (elranatamab) Triple-class relapsed/refractory multiple myeloma in adult patients Approved August 2023 Approved December 2023 Approved March 2024 Talzenna (talazoparib) Combination with Xtandi (enzalutamide) for adult patients with HRR gene-mutated mCRPC (c) Approved June 2023 Approved January 2024 Approved January 2024 Treatment of adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC) Approved October 2018 Approved June 2019 Approved January 2024 Beqvez (fidanacogene elaparvovec) (d) Moderate to severe hemophilia B in adults Approved April 2024 Approved July 2024 Filed June 2024 Xtandi (enzalutamide) (e) nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR) Approved November 2023 Approved April 2024 Hympavzi (marstacimab-hncq) Hemophilia A and B Approved October 2024 Filed October 2023 Filed February 2024 Emblaveo (aztreonam-avibactam) (f) Treatment of infections in adult patients caused by Gram-negative bacteria with limited or no treatment options Approved April 2024 Padcev (enfortumab vedotin-ejfv) (g) In combination with Keytruda \u00ae (h) (pembrolizumab) for locally advanced or metastatic urothelial cancer in adults Approved December 2023 Approved August 2024 Approved September 2024 Tivdak (tisotumab vedotin-tftv) (i) Recurrent or metastatic cervical cancer with disease progression on or after first-line therapy Approved April 2024 Filed February 2024 Filed April    2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron KP.2-adapted (j) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 12 years of age and older Approved August  2024 Approved September 2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron JN.1-adapted Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months of age and older Approved July 2024 Approved August 2024 Ngenla (somatrogon) (k) Adult growth hormone deficiency Filed June 2024 Adcetris (brentuximab vedotin) (l) Relapsed/refractory diffuse large B-cell lymphoma Filed July 2024 49 ^ For the U.S., the filing date is the date on which the FDA accepted our submission.",
      "score": 0.9986
    },
    {
      "sent": "Approved April 2023 Approved March 2024 Approved March 2024 TicoVac (Vaccine) Active immunization to prevent tick-borne encephalitis in individuals 1 year of age and older Approved August 2021 Approved March 2024 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura in adults Approved February 2020 Approved April 2022 Prevention of episodic migraine in adults Approved May 2021 Approved April 2022 Penbraya (Vaccine) Active immunization to prevent serogroups ABCWY meningococcal infections in adolescents and young adults 10 through 25 years of age Approved October 2023 Filed June 2023 Abrysvo (Vaccine) Active immunization of pregnant individuals for the prevention of lower respiratory tract disease caused by RSV in infants from birth through 6 months of age Approved August 2023 Approved August 2023 Approved January 2024 Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older Approved May 2023 Approved August 2023 Approved March 2024 Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age Approved October 2024 Filed June 2024 Velsipity (etrasimod) Moderately to severely active ulcerative colitis in adults Approved October 2023 Approved February 2024 Filed June 2024 Braftovi (encorafenib) and Mektovi (binimetinib) (b) BRAF V600E -mutant metastatic non-small cell lung cancer in adult patients Approved October 2023 Approved August 2024 Elrexfio (elranatamab) Triple-class relapsed/refractory multiple myeloma in adult patients Approved August 2023 Approved December 2023 Approved March 2024 Talzenna (talazoparib) Combination with Xtandi (enzalutamide) for adult patients with HRR gene-mutated mCRPC (c) Approved June 2023 Approved January 2024 Approved January 2024 Treatment of adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC) Approved October 2018 Approved June 2019 Approved January 2024 Beqvez (fidanacogene elaparvovec) (d) Moderate to severe hemophilia B in adults Approved April 2024 Approved July 2024 Filed June 2024 Xtandi (enzalutamide) (e) nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR) Approved November 2023 Approved April 2024 Hympavzi (marstacimab-hncq) Hemophilia A and B Approved October 2024 Filed October 2023 Filed February 2024 Emblaveo (aztreonam-avibactam) (f) Treatment of infections in adult patients caused by Gram-negative bacteria with limited or no treatment options Approved April 2024 Padcev (enfortumab vedotin-ejfv) (g) In combination with Keytruda \u00ae (h) (pembrolizumab) for locally advanced or metastatic urothelial cancer in adults Approved December 2023 Approved August 2024 Approved September 2024 Tivdak (tisotumab vedotin-tftv) (i) Recurrent or metastatic cervical cancer with disease progression on or after first-line therapy Approved April 2024 Filed February 2024 Filed April    2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron KP.2-adapted (j) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 12 years of age and older Approved August  2024 Approved September 2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron JN.1-adapted Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months of age and older Approved July 2024 Approved August 2024 Ngenla (somatrogon) (k) Adult growth hormone deficiency Filed June 2024 Adcetris (brentuximab vedotin) (l) Relapsed/refractory diffuse large B-cell lymphoma Filed July 2024 49 ^ For the U.S., the filing date is the date on which the FDA accepted our submission.",
      "score": 0.9986
    },
    {
      "sent": "Approved April 2023 Approved March 2024 Approved March 2024 TicoVac (Vaccine) Active immunization to prevent tick-borne encephalitis in individuals 1 year of age and older Approved August 2021 Approved March 2024 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura in adults Approved February 2020 Approved April 2022 Prevention of episodic migraine in adults Approved May 2021 Approved April 2022 Penbraya (Vaccine) Active immunization to prevent serogroups ABCWY meningococcal infections in adolescents and young adults 10 through 25 years of age Approved October 2023 Filed June 2023 Abrysvo (Vaccine) Active immunization of pregnant individuals for the prevention of lower respiratory tract disease caused by RSV in infants from birth through 6 months of age Approved August 2023 Approved August 2023 Approved January 2024 Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older Approved May 2023 Approved August 2023 Approved March 2024 Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age Approved October 2024 Filed June 2024 Velsipity (etrasimod) Moderately to severely active ulcerative colitis in adults Approved October 2023 Approved February 2024 Filed June 2024 Braftovi (encorafenib) and Mektovi (binimetinib) (b) BRAF V600E -mutant metastatic non-small cell lung cancer in adult patients Approved October 2023 Approved August 2024 Elrexfio (elranatamab) Triple-class relapsed/refractory multiple myeloma in adult patients Approved August 2023 Approved December 2023 Approved March 2024 Talzenna (talazoparib) Combination with Xtandi (enzalutamide) for adult patients with HRR gene-mutated mCRPC (c) Approved June 2023 Approved January 2024 Approved January 2024 Treatment of adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC) Approved October 2018 Approved June 2019 Approved January 2024 Beqvez (fidanacogene elaparvovec) (d) Moderate to severe hemophilia B in adults Approved April 2024 Approved July 2024 Filed June 2024 Xtandi (enzalutamide) (e) nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR) Approved November 2023 Approved April 2024 Hympavzi (marstacimab-hncq) Hemophilia A and B Approved October 2024 Filed October 2023 Filed February 2024 Emblaveo (aztreonam-avibactam) (f) Treatment of infections in adult patients caused by Gram-negative bacteria with limited or no treatment options Approved April 2024 Padcev (enfortumab vedotin-ejfv) (g) In combination with Keytruda \u00ae (h) (pembrolizumab) for locally advanced or metastatic urothelial cancer in adults Approved December 2023 Approved August 2024 Approved September 2024 Tivdak (tisotumab vedotin-tftv) (i) Recurrent or metastatic cervical cancer with disease progression on or after first-line therapy Approved April 2024 Filed February 2024 Filed April    2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron KP.2-adapted (j) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 12 years of age and older Approved August  2024 Approved September 2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron JN.1-adapted Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months of age and older Approved July 2024 Approved August 2024 Ngenla (somatrogon) (k) Adult growth hormone deficiency Filed June 2024 Adcetris (brentuximab vedotin) (l) Relapsed/refractory diffuse large B-cell lymphoma Filed July 2024 49 ^ For the U.S., the filing date is the date on which the FDA accepted our submission.",
      "score": 0.9986
    }
  ],
  "top_negative": [
    {
      "sent": "NDA New Drug Application Nimbus Nimbus Therapeutics, LLC nmCRPC non-metastatic castration-resistant prostate cancer nmCSPC non-metastatic castration-sensitive prostate cancer NSCLC non-small cell lung cancer ODT oral disintegrating tablet ORD Oncology Research and Development OTC over-the-counter Paxlovid (a) an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets) PC1 Pfizer CentreOne Pharmacia Pharmacia LLC (formerly Pharmacia Corporation) PP&E Property, plant and equipment PRD Pfizer Research and Development Prevnar family Includes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult) PsA psoriatic arthritis QTD Quarter-to-date or three months ended RA rheumatoid arthritis RCC renal cell carcinoma R&D research and development RSV respiratory syncytial virus S&P S&P Global (formerly Standard & Poor\u2019s) Seagen Seagen Inc.",
      "score": -0.9349
    },
    {
      "sent": "NDA New Drug Application Nimbus Nimbus Therapeutics, LLC nmCRPC non-metastatic castration-resistant prostate cancer nmCSPC non-metastatic castration-sensitive prostate cancer NSCLC non-small cell lung cancer ODT oral disintegrating tablet ORD Oncology Research and Development OTC over-the-counter Paxlovid (a) an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets) PC1 Pfizer CentreOne Pharmacia Pharmacia LLC (formerly Pharmacia Corporation) PP&E Property, plant and equipment PRD Pfizer Research and Development Prevnar family Includes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult) PsA psoriatic arthritis QTD Quarter-to-date or three months ended RA rheumatoid arthritis RCC renal cell carcinoma R&D research and development RSV respiratory syncytial virus S&P S&P Global (formerly Standard & Poor\u2019s) Seagen Seagen Inc.",
      "score": -0.9349
    },
    {
      "sent": "Paxlovid has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death.",
      "score": -0.8807
    }
  ],
  "forward_snippets": [
    "The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements.",
    "We will finalize the amounts recognized as soon as possible but no later than one year from the acquisition date.",
    "The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements.",
    "We will finalize the amounts recognized as soon as possible but no later than one year from the acquisition date.",
    "common shareholders ( 0.59 ) 0.47 The unaudited supplemental pro forma consolidated results do not purport to reflect what the combined company\u2019s results of operations would have been had the acquisition occurred on January 1,\nguidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements."
  ],
  "curated_text": "Symbol: PFE. Year: 2024. Period: Q1. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Approved April 2023 Approved March 2024 Approved March 2024 TicoVac (Vaccine) Active immunization to prevent tick-borne encephalitis in individuals 1 year of age and older Approved August 2021 Approved March 2024 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura in adults Approved February 2020 Approved April 2022 Prevention of episodic migraine in adults Approved May 2021 Approved April 2022 Penbraya (Vaccine) Active immunization to prevent serogroups ABCWY meningococcal infections in adolescents and young adults 10 through 25 years of age Approved October 2023 Filed June 2023 Abrysvo (Vaccine) Active immunization of pregnant individuals for the prevention of lower respiratory tract disease caused by RSV in infants from birth through 6 months of age Approved August 2023 Approved August 2023 Approved January 2024 Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older Approved May 2023 Approved August 2023 Approved March 2024 Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age Approved October 2024 Filed June 2024 Velsipity (etrasimod) Moderately to severely active ulcerative colitis in adults Approved October 2023 Approved February 2024 Filed June 2024 Braftovi (encorafenib) and Mektovi (binimetinib) (b) BRAF V600E -mutant metastatic non-small cell lung cancer in adult patients Approved October 2023 Approved August 2024 Elrexfio (elranatamab) Triple-class relapsed/refractory multiple myeloma in adult patients Approved August 2023 Approved December 2023 Approved March 2024 Talzenna (talazoparib) Combination with Xtandi (enzalutamide) for adult patients with HRR gene-mutated mCRPC (c) Approved June 2023 Approved January 2024 Approved January 2024 Treatment of adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC) Approved October 2018 Approved June 2019 Approved January 2024 Beqvez (fidanacogene elaparvovec) (d) Moderate to severe hemophilia B in adults Approved April 2024 Approved July 2024 Filed June 2024 Xtandi (enzalutamide) (e) nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR) Approved November 2023 Approved April 2024 Hympavzi (marstacimab-hncq) Hemophilia A and B Approved October 2024 Filed October 2023 Filed February 2024 Emblaveo (aztreonam-avibactam) (f) Treatment of infections in adult patients caused by Gram-negative bacteria with limited or no treatment options Approved April 2024 Padcev (enfortumab vedotin-ejfv) (g) In combination with Keytruda \u00ae (h) (pembrolizumab) for locally advanced or metastatic urothelial cancer in adults Approved December 2023 Approved August 2024 Approved September 2024 Tivdak (tisotumab vedotin-tftv) (i) Recurrent or metastatic cervical cancer with disease progression on or after first-line therapy Approved April 2024 Filed February 2024 Filed April    2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron KP.2-adapted (j) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 12 years of age and older Approved August  2024 Approved September 2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron JN.1-adapted Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months of age and older Approved July 2024 Approved August 2024 Ngenla (somatrogon) (k) Adult growth hormone deficiency Filed June 2024 Adcetris (brentuximab vedotin) (l) Relapsed/refractory diffuse large B-cell lymphoma Filed July 2024 49 ^ For the U.S., the filing date is the date on which the FDA accepted our submission. Approved April 2023 Approved March 2024 Approved March 2024 TicoVac (Vaccine) Active immunization to prevent tick-borne encephalitis in individuals 1 year of age and older Approved August 2021 Approved March 2024 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura in adults Approved February 2020 Approved April 2022 Prevention of episodic migraine in adults Approved May 2021 Approved April 2022 Penbraya (Vaccine) Active immunization to prevent serogroups ABCWY meningococcal infections in adolescents and young adults 10 through 25 years of age Approved October 2023 Filed June 2023 Abrysvo (Vaccine) Active immunization of pregnant individuals for the prevention of lower respiratory tract disease caused by RSV in infants from birth through 6 months of age Approved August 2023 Approved August 2023 Approved January 2024 Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older Approved May 2023 Approved August 2023 Approved March 2024 Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age Approved October 2024 Filed June 2024 Velsipity (etrasimod) Moderately to severely active ulcerative colitis in adults Approved October 2023 Approved February 2024 Filed June 2024 Braftovi (encorafenib) and Mektovi (binimetinib) (b) BRAF V600E -mutant metastatic non-small cell lung cancer in adult patients Approved October 2023 Approved August 2024 Elrexfio (elranatamab) Triple-class relapsed/refractory multiple myeloma in adult patients Approved August 2023 Approved December 2023 Approved March 2024 Talzenna (talazoparib) Combination with Xtandi (enzalutamide) for adult patients with HRR gene-mutated mCRPC (c) Approved June 2023 Approved January 2024 Approved January 2024 Treatment of adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC) Approved October 2018 Approved June 2019 Approved January 2024 Beqvez (fidanacogene elaparvovec) (d) Moderate to severe hemophilia B in adults Approved April 2024 Approved July 2024 Filed June 2024 Xtandi (enzalutamide) (e) nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR) Approved November 2023 Approved April 2024 Hympavzi (marstacimab-hncq) Hemophilia A and B Approved October 2024 Filed October 2023 Filed February 2024 Emblaveo (aztreonam-avibactam) (f) Treatment of infections in adult patients caused by Gram-negative bacteria with limited or no treatment options Approved April 2024 Padcev (enfortumab vedotin-ejfv) (g) In combination with Keytruda \u00ae (h) (pembrolizumab) for locally advanced or metastatic urothelial cancer in adults Approved December 2023 Approved August 2024 Approved September 2024 Tivdak (tisotumab vedotin-tftv) (i) Recurrent or metastatic cervical cancer with disease progression on or after first-line therapy Approved April 2024 Filed February 2024 Filed April    2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron KP.2-adapted (j) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 12 years of age and older Approved August  2024 Approved September 2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron JN.1-adapted Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months of age and older Approved July 2024 Approved August 2024 Ngenla (somatrogon) (k) Adult growth hormone deficiency Filed June 2024 Adcetris (brentuximab vedotin) (l) Relapsed/refractory diffuse large B-cell lymphoma Filed July 2024 49 ^ For the U.S., the filing date is the date on which the FDA accepted our submission. Approved April 2023 Approved March 2024 Approved March 2024 TicoVac (Vaccine) Active immunization to prevent tick-borne encephalitis in individuals 1 year of age and older Approved August 2021 Approved March 2024 Nurtec ODT/Vydura (rimegepant) Acute treatment of migraine with or without aura in adults Approved February 2020 Approved April 2022 Prevention of episodic migraine in adults Approved May 2021 Approved April 2022 Penbraya (Vaccine) Active immunization to prevent serogroups ABCWY meningococcal infections in adolescents and young adults 10 through 25 years of age Approved October 2023 Filed June 2023 Abrysvo (Vaccine) Active immunization of pregnant individuals for the prevention of lower respiratory tract disease caused by RSV in infants from birth through 6 months of age Approved August 2023 Approved August 2023 Approved January 2024 Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older Approved May 2023 Approved August 2023 Approved March 2024 Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age Approved October 2024 Filed June 2024 Velsipity (etrasimod) Moderately to severely active ulcerative colitis in adults Approved October 2023 Approved February 2024 Filed June 2024 Braftovi (encorafenib) and Mektovi (binimetinib) (b) BRAF V600E -mutant metastatic non-small cell lung cancer in adult patients Approved October 2023 Approved August 2024 Elrexfio (elranatamab) Triple-class relapsed/refractory multiple myeloma in adult patients Approved August 2023 Approved December 2023 Approved March 2024 Talzenna (talazoparib) Combination with Xtandi (enzalutamide) for adult patients with HRR gene-mutated mCRPC (c) Approved June 2023 Approved January 2024 Approved January 2024 Treatment of adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC) Approved October 2018 Approved June 2019 Approved January 2024 Beqvez (fidanacogene elaparvovec) (d) Moderate to severe hemophilia B in adults Approved April 2024 Approved July 2024 Filed June 2024 Xtandi (enzalutamide) (e) nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR) Approved November 2023 Approved April 2024 Hympavzi (marstacimab-hncq) Hemophilia A and B Approved October 2024 Filed October 2023 Filed February 2024 Emblaveo (aztreonam-avibactam) (f) Treatment of infections in adult patients caused by Gram-negative bacteria with limited or no treatment options Approved April 2024 Padcev (enfortumab vedotin-ejfv) (g) In combination with Keytruda \u00ae (h) (pembrolizumab) for locally advanced or metastatic urothelial cancer in adults Approved December 2023 Approved August 2024 Approved September 2024 Tivdak (tisotumab vedotin-tftv) (i) Recurrent or metastatic cervical cancer with disease progression on or after first-line therapy Approved April 2024 Filed February 2024 Filed April    2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron KP.2-adapted (j) Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 12 years of age and older Approved August  2024 Approved September 2024 Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron JN.1-adapted Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months of age and older Approved July 2024 Approved August 2024 Ngenla (somatrogon) (k) Adult growth hormone deficiency Filed June 2024 Adcetris (brentuximab vedotin) (l) Relapsed/refractory diffuse large B-cell lymphoma Filed July 2024 49 ^ For the U.S., the filing date is the date on which the FDA accepted our submission. Top negative sentences: NDA New Drug Application Nimbus Nimbus Therapeutics, LLC nmCRPC non-metastatic castration-resistant prostate cancer nmCSPC non-metastatic castration-sensitive prostate cancer NSCLC non-small cell lung cancer ODT oral disintegrating tablet ORD Oncology Research and Development OTC over-the-counter Paxlovid (a) an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets) PC1 Pfizer CentreOne Pharmacia Pharmacia LLC (formerly Pharmacia Corporation) PP&E Property, plant and equipment PRD Pfizer Research and Development Prevnar family Includes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult) PsA psoriatic arthritis QTD Quarter-to-date or three months ended RA rheumatoid arthritis RCC renal cell carcinoma R&D research and development RSV respiratory syncytial virus S&P S&P Global (formerly Standard & Poor\u2019s) Seagen Seagen Inc. NDA New Drug Application Nimbus Nimbus Therapeutics, LLC nmCRPC non-metastatic castration-resistant prostate cancer nmCSPC non-metastatic castration-sensitive prostate cancer NSCLC non-small cell lung cancer ODT oral disintegrating tablet ORD Oncology Research and Development OTC over-the-counter Paxlovid (a) an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets) PC1 Pfizer CentreOne Pharmacia Pharmacia LLC (formerly Pharmacia Corporation) PP&E Property, plant and equipment PRD Pfizer Research and Development Prevnar family Includes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult) PsA psoriatic arthritis QTD Quarter-to-date or three months ended RA rheumatoid arthritis RCC renal cell carcinoma R&D research and development RSV respiratory syncytial virus S&P S&P Global (formerly Standard & Poor\u2019s) Seagen Seagen Inc. Paxlovid has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. Forward-looking snippets: The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements. We will finalize the amounts recognized as soon as possible but no later than one year from the acquisition date. The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements. We will finalize the amounts recognized as soon as possible but no later than one year from the acquisition date. common shareholders ( 0.59 ) 0.47 The unaudited supplemental pro forma consolidated results do not purport to reflect what the combined company\u2019s results of operations would have been had the acquisition occurred on January 1,\nguidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements."
}